# EDGAR Filing Document

**Accession Number:** 0001643918
**File Stem:** 0001214659-23-003749
**Filing Date:** 2023-3
**Character Count:** 7101
**Document Hash:** de32ff8e2fcfa1ef75c2b465402b69c9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001214659-23-003749.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0001214659-23-003749

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230310

**FILED AS OF DATE**: 20230310

**DATE AS OF CHANGE**: 20230310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Midatech Pharma Plc
- **CENTRAL INDEX KEY:** 0001643918
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37652
- **FILM NUMBER:** 23723594

**BUSINESS ADDRESS:**
- **STREET 1:** 1 CASPIAN POINT
- **STREET 2:** CASPIAN WAY
- **CITY:** CARDIFF
- **STATE:** X0
- **ZIP:** CF10 4DQ
- **BUSINESS PHONE:** 44 (0)1235 888300

**MAIL ADDRESS:**
- **STREET 1:** 1 CASPIAN POINT
- **STREET 2:** CASPIAN WAY
- **CITY:** CARDIFF
- **STATE:** X0
- **ZIP:** CF10 4DQ

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16 OF THE** 

**SECURITIES EXCHANGE ACT OF 1934**

For the month of March 2023

Commission File Number 001-37652

**<u>Midatech Pharma PLC</u>**

**(Translation of registrant's name into English)**

**1 Caspian Point, Caspian Way, <u>Cardiff, CF10 4DQ, United Kingdom</u>**

**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F **☐**

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): **☐**

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): **☐**

**EXPLANATORY NOTE**

On March 10, 2023, Midatech Pharma PLC (the "Company") issued a press release announcing the correction of certain typographical errors identified within the Company's Circular and Notice of General Meeting (the "Circular") previously posted to its shareholders with respect to a General Meeting to be held on March 24, 2023. A copy of the press release is furnished hereto as Exhibit 99.1.

*The information in the attached Exhibit 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.*

**<u>SUBMITTED HEREWITH</u>**

Attached to the Registrant's Form 6-K filing for the month of March 2023 is:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | Press Release, dated March 10, 2023. |

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Midatech Pharma PLC** | **Midatech Pharma PLC** |
| Date: March 10, 2023 | By: | /s/ Stephen Stamp |
|  |  | &nbsp;&nbsp;&nbsp;Stephen Stamp |
|  |  | &nbsp;&nbsp;&nbsp;Chief Executive Officer and |
|  |  | &nbsp;&nbsp;&nbsp;Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

10 March 2023

**Midatech Pharma PLC**

("Midatech" or the "Company")

**Further re**: **Notice of General Meeting - Correction of Typographical Errors**

Further to the announcement made on 8 March 2023 providing notice of a general meeting (the "**GM**") of the Company to be held on 24 March 2023, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM (the "**Notice**") and form of proxy (the "**Form of Proxy**"), the Company announces the following corrections to certain typographical errors identified within the Notice and Form of Proxy:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Resolution 4 of the Notice ()"**Resolution 4**") refers to a proposed authority to waive pre-emption rights in respect
of the allotment authority sought by resolution 2 of the Notice which is limited to an aggregate nominal amount of £1,911,169.68.
Accordingly, the waiver of pre-emption rights authority sought by Resolution 4 should be an amount of £1,911,169.68 (not £2,905,400.59
as currently stated in the Notice);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Resolution 5 of the Notice ()"**Resolution 5**") refers to a proposed authority to waive pre-emption rights in respect
of the allotment authority sought by resolution 3 of the Notice which is limited to an aggregate nominal amount of £2,300,000.00.
Accordingly, the waiver of pre-emption rights authority sought by Resolution 5 should be an amount of £2,300,000.00 (not £4,200,000
as currently stated in the Notice); and

&nbsp;&nbsp;&nbsp;&nbsp;· Resolution 4 as described on the Form of Proxy incorrectly states that it is "*To authorise grant the Directors authority to allot shares in the Company in connection with the grant of the A Warrants, the B Warrants, the Ladenburg Warrants, the Waiver Warrants and the Pre-Funded Warrants*" (which effectively duplicates resolution 2 of the Form of Proxy). In accordance with the resolutions
set out in the Notice, resolution 4 of the Form of Proxy should instead state that it is "*To disapply statutory pre-emption rights in connection with the grant of the A Warrants, the B Warrants, the Ladenburg Warrants, the Waiver Warrants and the Pre-Funded Warrants* ".

As such errors are administrative in nature, no new Notice will be published and the aforementioned amendments to Resolution 4 and Resolution 5 will be effected by a motion to be passed at the GM. Furthermore, no new Form of Proxy will be posted to shareholders but a copy of the corrected Form of Proxy will be made available on the Company's website at: www.midatechpharma.com/. Any shareholder who wishes to change any proxy instructions already submitted may do so by submitting a new proxy appointment using the method set out in the notes to the Notice.

---

| |
|:---|
| **For more information, please contact**:<br> **Midatech Pharma PLC** |
| Stephen Stamp, CEO, CFO |
| Tel: +44 (0)29 2048 0180 |
| www.midatechpharma.com |
| **Strand Hanson Limited (Nominated Adviser and Broker)** |
| James Dance / Matthew Chandler / Rob Patrick |
| Tel: +44 (0)20 7409 3494 |

---

---

| |
|:---|
| **IFC Advisory Limited (Financial PR and UK Investor Relations)** |
| Tim Metcalfe / Graham Herring |
| Tel: +44 (0)20 3934 6630 |
| Email: midatech@investor-focus.co.uk |
| **Edison Group (US Investor Relations)**<br> Alyssa Factor<br> Tel: +1 (860) 573 9637<br> Email: afactor@edisongroup.com<br>|

---